HRS

Kardium announces positive 1-year outcomes for PULSE-EU trial with the Globe® System, showing promise for improving the treatment of atrial fibrillation

Retrieved on: 
Mercredi, mai 29, 2024
Research, Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Patient, HRS, Cardiac tamponade, Inc., Paroxysmal attack, Death, Persistent, Mount Sinai Hospital, Atrial fibrillation, Fluoroscopy, Femoral vein, Freedom, Pulmonary vein stenosis, Annual general meeting

Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF), announced positive results of the 1-year outcomes of the First-in-Human PULSE-EU Trial.

Key Points: 
  • Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF), announced positive results of the 1-year outcomes of the First-in-Human PULSE-EU Trial.
  • “The Globe System achieved outstanding freedom from atrial arrhythmia in both Paroxysmal and Persistent patients, with no device- or procedure-related major adverse events.
  • “These excellent results of the PULSE-EU Trial reflect Kardium’s ongoing dedication to develop the best treatment for Atrial Fibrillation”, said Kevin Chaplin, CEO of Kardium.
  • Kardium has built an outstanding team, who have worked with top medical advisors to develop the Globe System.

FDA Grants AI-Powered Notal Vision Home OCT "SCANLY" De Novo Marketing Authorization

Retrieved on: 
Jeudi, mai 16, 2024
Cloud, Insurance, Patient, Retina, Doctor of Philosophy, HRS, NOA, AMD, Neovascularization, Medicare, Health, Randomized controlled trial, OCT, Retinal, FDA, Digital, CPT, Disease, MD, De novo, Biomarker, Physician, Artificial intelligence, Home, TRO, Ophthalmology, Medical imaging

First-ever home retinal imaging service to monitor wet AMD, the leading cause of blindness for older patients

Key Points: 
  • Manassas, Virginia--(Newsfile Corp. - May 16, 2024) - Digital healthcare provider, Notal Vision, announced today that the US Food and Drug Administration (FDA) has granted De Novo authorization for its patient self-operated SCANLY® Home OCT device.
  • SCANLY captures spectral-domain optical coherence tomography (OCT) images in a 10 by 10-degree area centered on the point of fixation.
  • The proprietary, artificial intelligence (AI)-based Notal OCT Analyzer (NOA) segments and estimates the volume of hypo-reflective spaces (HRS)-important biomarkers in managing nvAMD-on OCT images.
  • Notal Vision's SCANLY Home OCT has the potential to support current and future advances in retinal disease management.

Philips presents study results at Heart Rhythm Annual Meeting demonstrating benefits of its AI-powered cardiac monitoring solutions

Retrieved on: 
Vendredi, mai 17, 2024
MCOT, Partnership, Syncope, Patient, Cardiovascular disease, No. 166 Squadron RAF, HRS, Survival, Arrhythmia, USD, Health, Lead management, ICPS, Algorithm, Consciousness, University, Diagnosis, DNN, Safety, Stroke, Infection, Emergency, Ventricular tachycardia, AI, AEX, PHG, Convention center, Research, ILR, ECG, Biomarker, Atrial fibrillation, Journal, Physician, Medtronic, Medical device

Syncope may be caused by a serious heart condition and cardiac monitoring solutions are often used to detect adverse heart rate and/or rhythm events to improve how syncope patients are diagnosed and managed.

Key Points: 
  • Syncope may be caused by a serious heart condition and cardiac monitoring solutions are often used to detect adverse heart rate and/or rhythm events to improve how syncope patients are diagnosed and managed.
  • Philips’ study reveals that AI-powered ECG biomarker technology may help to identify patients with significant intermittent bradyarrhythmia, potentially improving timely diagnosis and management.
  • While ambulatory cardiac monitors are frequently used to diagnose arrhythmias, their impact on clinical decision-making has not been extensively studied.
  • For more information on Philips’ presence at HRS, join in person at booth #1135 in the Boston Convention and Exhibition Center or visit Heart Rhythm 2024 .

Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Retrieved on: 
Jeudi, mai 16, 2024
Research, Surgery, Medical Devices, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, Science, Abstract, Patient, Heart Rhythm Society, HRS, Annual general meeting

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
  • “We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case presentation at the prestigious HRS meeting,” said Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences.
  • “The preclinical and initial clinical outcomes from studies with our surgical clamp and catheter are encouraging and we continue to believe that CellFX nsPFA can meaningfully advance the treatment of atrial fibrillation.”
    “Our innovative energy delivery platform technology allows us to uniquely meet the needs of both cardiac surgeons and EPs who together treat all types of patients with cardiac ailments,” added President and Chief Executive Officer Burke T. Barrett.
  • “I am looking forward to speaking with, now as part of Pulse Biosciences, the many providers in the clinical community I have met over the years.”
    CellFX nsPFA technology will be featured at the following times at the HRS 2024 Annual Meeting:

HRS 2024: Vektor Medical’s vMap Technology to be Highlighted in Rhythm Theater and Eight Posters

Retrieved on: 
Mercredi, mai 15, 2024
Cardiology, Biotechnology, Technology, Health, Biometrics, Wearables, Mobile Technology, Health Technology, Medical Devices, Software, Artificial Intelligence, Telemedicine, Virtual Medicine, Vector, HRS, Research, Electrophysiology, Arrhythmia, Rhythm, Physician, DRS, Medicine, Medical device

The research and presentations at HRS further demonstrate the unique ability of vMap to assist physicians with both focal and fibrillation-type arrhythmias.

Key Points: 
  • The research and presentations at HRS further demonstrate the unique ability of vMap to assist physicians with both focal and fibrillation-type arrhythmias.
  • Attendees can experience vMap at the Vektor Medical booth (#669), hear expert perspectives from leading KOLs during the Rhythm Theater, and read more about vMap in various scientific posters and presentations.
  • “HRS is a vital opportunity for us to connect with the electrophysiology community, share our latest data, and receive invaluable feedback,” said Rob Krummen, CEO of Vektor Medical.
  • “Our team is deeply committed to advancing cardiac care, and I’m excited to see how vMap continues to improve patient outcomes and streamline procedures.

InfoBionic.Ai Announces Next-Generation Advancements in the MoMe ARC® Suite of Products

Retrieved on: 
Mardi, mai 14, 2024
MOME, Patch, Sensor, Patient, HRS, Physician, FDA, Ecosystem, ECG, Intelligence, Medical device

BOSTON, May 14, 2024 /PRNewswire-PRWeb/ -- InfoBionic.Ai, an innovative digital health company providing industry-validated highest quality ECG and AI-powered diagnostic remote patient monitoring solutions, is pleased to announce a series of new advancements that usher in the next generation of the MoMe ARC® product suite. "Our continued pursuit of innovation has yielded new advancements in our MoMe ARC® suite of products, from our next-generation MoMe ARC® 6-Lead Sensor and upcoming MoMe ARC® 1-Lead Patch to the powerful business intelligence of MoMe Analytics™," says Stuart Long, CEO of InfoBionic.Ai. "We are proud to unveil a comprehensive suite of cutting-edge advancements that will equip providers with a powerful ecosystem of solutions designed to optimize every aspect of remote cardiac monitoring—from patient comfort and data quality to operational efficiency and clinical performance."

Key Points: 
  • "Our continued pursuit of innovation has yielded new advancements in our MoMe ARC® suite of products, from our next-generation MoMe ARC® 6-Lead Sensor and upcoming MoMe ARC® 1-Lead Patch to the powerful business intelligence of MoMe Analytics™," says Stuart Long, CEO of InfoBionic.Ai.
  • "Our continued pursuit of innovation has yielded new advancements in our MoMe ARC® suite of products, from our next-generation MoMe ARC® 6-Lead Sensor and upcoming MoMe ARC® 1-Lead Patch to the powerful business intelligence of MoMe Analytics™."
  • It will be the next addition to the MoMe ARC® suite of patient-worn sensors.
  • MoMe Analytics™ in limited release will help practices gain business and clinical performance never seen in remote cardiac monitoring.

Innovative Health Reports Strong Growth in Cost and Environmental Savings for EP Labs at the 2024 Heart Rhythm Society Conference

Retrieved on: 
Lundi, mai 13, 2024
Heart Rhythm, HRS, Health, Innovation, FDA, Carbon, Growth, Electrophysiology, EP, Environment, Physician, Pharmaceutical industry

SCOTTSDALE, Ariz., May 13, 2024 /PRNewswire-PRWeb/ -- Innovative Health, Inc. today announced that recent growth in single-use device reprocessing has delivered significant financial and environmental benefits to U.S. electrophysiology labs. These reductions in cost and carbon emissions will help shape conversations around the value of medical technology re-use at the annual Heart Rhythm Society conference in Boston.

Key Points: 
  • Innovative Health will present recent FDA clearances and new initiatives to help labs reduce costs and their environmental footprint.
  • SCOTTSDALE, Ariz., May 13, 2024 /PRNewswire-PRWeb/ -- Innovative Health, Inc. today announced that recent growth in single-use device reprocessing has delivered significant financial and environmental benefits to U.S. electrophysiology labs.
  • These reductions in cost and carbon emissions will help shape conversations around the value of medical technology re-use at the annual Heart Rhythm Society conference in Boston.
  • Last year, Innovative Health expanded its partnerships with EP labs across the country by 25% and grew cost reductions to its partner labs by 35%.

HEART RHYTHM 2024: LEADING HEART RHYTHM MEETING ASSEMBLES FOR 45TH YEAR TO UNVEIL SCIENTIFIC DISCOVERIES AND INNOVATIONS TO GLOBAL EP COMMUNITY

Retrieved on: 
Lundi, mai 13, 2024
Online, FHRS, Faculty, HRS, American Heart Association, Business, Health, News, Convention, Woman, Travel, AFIB, Special, AHA, Ventricular fibrillation, Research, Electrophysiology, Shark, Shark Tank, Exclusive, Arrhythmia, Artificial intelligence, EP

BOSTON, May 13, 2024 /PRNewswire/ -- On Thursday, the 45th annual Heart Rhythm Society (HRS) meeting, Heart Rhythm 2024, will kick off in Boston and online, bringing together more than 8,400 clinicians, scientists, researchers, and innovators from the field of cardiac pacing and electrophysiology. This year's meeting received the highest number of late-breaking abstract submissions for its Late-Breaking Clinical Trial and Science sessions in the 45-year history of the meeting.

Key Points: 
  • This year's meeting received the highest number of late-breaking abstract submissions for its Late-Breaking Clinical Trial and Science sessions in the 45-year history of the meeting.
  • Heart Rhythm 2024 will offer more than 200 sessions led by over 2,600 expert faculty and abstract presenters from around the world.
  • Attendees unable to travel to Boston may choose the Online-Only Experience to access live streaming and on-demand sessions remotely.
  • Scientists, clinicians, and HRS leadership will be available for interviews to further discuss specific sessions and innovations in heart rhythm care.

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on: 
Jeudi, mai 9, 2024
PFA, Physics, Safety, Arrhythmia, Catheter ablation, HRS, PVC, MD, Cardiac electrophysiology, Workflow, Mount Sinai Health System, Ventricular tachycardia, Cardiac cycle, Patient, Atrial fibrillation, Boston Scientific, Medical device

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points: 
  • First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
  • CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
  • The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
  • Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on: 
Jeudi, mai 9, 2024
PFA, Physics, Safety, Arrhythmia, Catheter ablation, HRS, PVC, MD, Cardiac electrophysiology, Workflow, Mount Sinai Health System, Ventricular tachycardia, Cardiac cycle, Patient, Atrial fibrillation, Boston Scientific, Medical device

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points: 
  • First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
  • CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
  • The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
  • Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.